Skip to main content
. Author manuscript; available in PMC: 2012 Mar 18.
Published in final edited form as: Kidney Int. 2010 Dec 22;79(6):678–685. doi: 10.1038/ki.2010.485

Figure 2. Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial primary outcome definitions.

Figure 2

Category 1, patients who achieved a complete remission by week 26 that was sustained to week 52; category 2, patients who achieved a partial remission at week 26 and then a complete remission at week 52; category 3, patients who achieved a partial remission by week 26 that was sustained to week 52; category 4, patients who achieved a partial remission at week 26 and then had recurrence of proteinuria before week 52; category 5, patients who achieved a partial remission before week 26 and then had a recurrence of proteinuria before week 26; category 6, patients who never had a urine protein/creatinine ratio (Up/c) <50% of the baseline value and an absolute value below 2 g/g. Participants with a baseline Up/c between 1 and 1.99 g/g were required to meet the 50% reduction in Up/c to meet the criteria of partial remission and <0.2 g/g for complete remission consistent with subjects entering with a baseline Up/c ≥2 g/g.